. . "8"^^ . "CLINICAL UTILITY OF MOLECULAR CHARACTERIZATION OF GASTRIC CANCERS BASED ON SOMATIC MUTATIONS AND GENE AMPLIFICATIONS"@en . . . . "Poster presenting clinical utility of molecular characterization of gastric cancer. According to the Czech national cancer register the prognosis of gastric cancer patients has remained unchanged over the course of the past 20 years. With a 5-year survival of just 30% (for all stages) it is the third most fatal malignancy of the gastrointestinal tract and sixth overall among solid cancers. The recent trends in discovery and use of biomarkers in other cancers have been mainly derived from detailed tumor profiling. Somatic mutations and gene amplifications are among the molecular aberations frequently studied. The conclusion is: Somatic mutations are not associated with localization or stage and are likely not factors in prognosis of the disease. Molecular classification of gastric cancer based on gene amplification patterns results in distinct tumor similarities that may have clinical relevance for clinical management of gastric cancer." . "Min\u00E1rik, Marek" . "RIV/26475821:_____/13:#0000191" . "P(NT13640)" . . . "3"^^ . "65708" . "CLINICAL UTILITY OF MOLECULAR CHARACTERIZATION OF GASTRIC CANCERS BASED ON SOMATIC MUTATIONS AND GENE AMPLIFICATIONS" . . . . "APC, CTNNB1, KRAS, BRAF, EGFR, PIK3CA, TP53"@en . . . . . . "RIV/26475821:_____/13:#0000191!RIV14-MZ0-26475821" . . . "[BFC94A3E3B0A]" . . . . . "CLINICAL UTILITY OF MOLECULAR CHARACTERIZATION OF GASTRIC CANCERS BASED ON SOMATIC MUTATIONS AND GENE AMPLIFICATIONS"@en . "CLINICAL UTILITY OF MOLECULAR CHARACTERIZATION OF GASTRIC CANCERS BASED ON SOMATIC MUTATIONS AND GENE AMPLIFICATIONS" . "Bel\u0161\u00E1nov\u00E1, Barbora" . "Poster presenting clinical utility of molecular characterization of gastric cancer. According to the Czech national cancer register the prognosis of gastric cancer patients has remained unchanged over the course of the past 20 years. With a 5-year survival of just 30% (for all stages) it is the third most fatal malignancy of the gastrointestinal tract and sixth overall among solid cancers. The recent trends in discovery and use of biomarkers in other cancers have been mainly derived from detailed tumor profiling. Somatic mutations and gene amplifications are among the molecular aberations frequently studied. The conclusion is: Somatic mutations are not associated with localization or stage and are likely not factors in prognosis of the disease. Molecular classification of gastric cancer based on gene amplification patterns results in distinct tumor similarities that may have clinical relevance for clinical management of gastric cancer."@en . . "Bene\u0161ov\u00E1, Lucie" .